In the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, people taking tirzepatide lost an average of 20.2% of their body weight over 72 weeks, compared with 13.7% for those taking semaglutide
Cummings: Between semaglutide and tirzepatide, tirzepatide is a little stronger on the usual (clinical trial) endpoints
after 12 months roughly 110-130% above baseline values
Safety profiles vary significantly : IV administration carries serious risks including anaphylaxis, hepatotoxicity, and potential endotoxin contamination, while oral supplements typically cause only mild gastrointestinal effects like flatulence or loose stools
This article will explore the relationship between glutathione and melanin, the biological pathways involved in skin pigmentation, and why the way you take this antioxidant changes everything